Vicious circles in inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 12, Issue 10, 2006, Pages 944-949

  Sonnenberg, Amnon ^a,b   Collins, Judith F ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Complications of IBD; Crohn's disease; Decision analysis; Health service research; Influence diagram; Simulation; Surgery of IBD

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; INFLIXIMAB; MESALAZINE; WARFARIN;

ADULT; AGED; ANALYTICAL PARAMETERS; ANEMIA; ANTIBIOTIC THERAPY; ARTICLE; ASCITES; CASE REPORT; CLINICAL ASSESSMENT; CLINICAL FEATURE; CROHN DISEASE; DEEP VEIN THROMBOSIS; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DRUG TREATMENT FAILURE; ENTERITIS; FEEDING APPARATUS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; INTERVENTION STUDY; INTESTINE LYMPHOMA; INTESTINE OBSTRUCTION; LUNG INFECTION; MALE; MALNUTRITION; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MEDICAL CARE; MEDICAL DECISION MAKING; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MYCOBACTERIUM INTRACELLULARE AVIUM; PATIENT CARE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; THERAPY DELAY; TOTAL PARENTERAL NUTRITION; TREATMENT OUTCOME;

ADULT; AGED; COMPUTER SIMULATION; CROHN DISEASE; DECISION MAKING; DECISION SUPPORT TECHNIQUES; DECISION TREES; DRUG THERAPY; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; LYMPHOMA; MALE; MALNUTRITION; MIDDLE AGED; THROMBOSIS;

EID: 33749370068     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.mib.0000231577.19301.95     Document Type: Article

References (18)

1. Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore). 1976;55:401-412.
2. von Tirpitz C, Reinshagen M. Management of osteoporosis in patients with gastrointestinal diseases. Eur J Gastroenterol Hepatol. 2003;15:869-876.
3. Irving PM, Pasi KJ, Rampton DS. Thombosis and inflammatory bowel disease. Clin Gastrotenterol Hepatol. 2005;3:617-628.
4. Gitkind MJ, Wright SC. Amyloidosis complicating inflammatory bowel disease. A case report and review of the literature. Dig Dis Sci. 1990;35:906-908.
5. Askling J, Brandt L, Lapidus A, et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut. 2005;54:617-622.
6. Gravallese EM, Kantrowitz FG. Arthritic manifestations of inflammatory bowel disease. Am J Gastroenterol. 1988;83:703-709. Review.
7. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat. 2004;15:280-294.
8. Sandborn WJ, Loftus EV. Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Gut. 2004;53:780-782.
9. Glazier KD, Palance AL, Griffel LH, et al. The ten-year single-center experience with 6-mercaptopurine in the treatment of inflammatory bowel disease. J Clin Gastroenterol. 2005;39:21-26.
10. Achkar JP, Shen B. Medical management of postoperative complications of inflammatory bowel disease: pouchitis and Crohn's disease recurrence. Curr Gastroenterol Rep. 2001;3:484-490.
11. Sonnenberg A, Vakil N. The benefit of negative tests in non-ulcer dyspepsia. Med Decis Making. 2002;22:199-207.
12. Sonnenberg A, Gavin MW. Timing of surgery for enterovesical fistula in Crohn's disease: decision analysis using a time-dependent compartment model. Inflamm Bowel Dis. 2000;6:280-285.
13. Sonnenberg A. Cost effectiveness of competing strategies to prevent or treat GORD-related dysphagia. Pharmacoeconomics. 2000;17:391-401.
14. Weiss HJ, Gershon ME. Production and Operations Management. Boston: Allyn and Bacon; 1989.
15. Krajewski LJ, Larry P, Ritzman LP. Operations Management: Strategy and Analysis, ed 5. Reading, MA: Addison-Wesley Publishing Company; 2000.
16. Hillier FS, Lieberman GJ. Introduction to Operations Research, ed 8. New York: McGraw Hill; 2005.
17. Malhotra S, Kondal A, Shafiq N, et al. A comparison of observational studies and controlled trials of heparin in ulcerative colitis. Int J Clin Pharmacol Ther. 2004;42:690-694.
18. Bloom S, Kiilerich S, Lassen MR, et al. Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis. Aliment Pharmacol Ther. 2004;19:871-878.